Cargando…

Antipsychotics with similar association kinetics at dopamine D(2) receptors differ in extrapyramidal side-effects

Detalles Bibliográficos
Autores principales:	Zeberg, Hugo, Sahlholm, Kristoffer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120954/ https://www.ncbi.nlm.nih.gov/pubmed/30177830 http://dx.doi.org/10.1038/s41467-018-04489-x

Ejemplares similares

Reply to ‘Antipsychotics with similar association kinetics at dopamine D(2) receptors differ in extrapyramidal side-effects’
por: Sykes, David A., et al.
Publicado: (2018)

Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D(2) receptors
por: Sykes, David A., et al.
Publicado: (2017)

Dopamine D(2) Receptor Agonist Binding Kinetics—Role of a Conserved Serine Residue
por: Ågren, Richard, et al.
Publicado: (2021)

Voltage-Dependent Dopamine Potency at D(1)-Like Dopamine Receptors
por: Ågren, Richard, et al.
Publicado: (2020)

Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis
por: Siafis, Spyridon, et al.
Publicado: (2023)

In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics
por: Ågren, Richard, et al.
Publicado: (2023)

Evidence for Two Modes of Binding of the Negative Allosteric Modulator SB269,652 to the Dopamine D(2) Receptor
por: Ågren, Richard, et al.
Publicado: (2021)

ANTIPSYCHOTIC-INDUCED VACUOUS CHEWING MOVEMENTS AND EXTRAPYRAMIDAL SIDE-EFFECTS ARE HIGHLY HERITABLE IN MICE
por: Crowley, James J., et al.
Publicado: (2010)

Antipsychotic Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD): Management of Extrapyramidal Side Effects
por: Ohno, Yukihiro, et al.
Publicado: (2019)

Ligand with Two Modes of Interaction with the Dopamine D(2) Receptor–An Induced-Fit Mechanism of Insurmountable Antagonism
por: Ågren, Richard, et al.
Publicado: (2020)

Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
por: Divac, Nevena, et al.
Publicado: (2014)

Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies
por: Ali, Tilahun, et al.
Publicado: (2021)

Dopamine-induced arrestin recruitment and desensitization of the dopamine D4 receptor is regulated by G protein-coupled receptor kinase-2
por: Burström, Viktor, et al.
Publicado: (2023)

Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics
por: Boloc, Daniel, et al.
Publicado: (2018)

Case report: Open bite as an extrapyramidal side effect with aripiprazole, a dopamine partial agonist
por: Sumi, Satoko, et al.
Publicado: (2022)

Akathisia as an Extrapyramidal Side Effect of Fluoxetine
por: Ajufo, Ijeoma, et al.
Publicado: (2021)

Major Genetic Risk Factors for Dupuytren's Disease Are Inherited From Neandertals
por: Ågren, Richard, et al.
Publicado: (2023)

The Beta-Arrestin-Biased Dopamine D(2) Receptor Ligand, UNC9994, Is a Partial Agonist at G-Protein-Mediated Potassium Channel Activation
por: Ågren, Richard, et al.
Publicado: (2018)

Extrapyramidal side effects with low doses of amisulpride
por: Mandal, Nikhiles, et al.
Publicado: (2014)

Interaction of Ligands for PET with the Dopamine D3 Receptor: In Silico and In Vitro Methods
por: Hsieh, Chia-Ju, et al.
Publicado: (2021)

Author Correction: Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics
por: Boloc, Daniel, et al.
Publicado: (2019)

Acute Extrapyramidal Side Effects from Smoked Haloperidol
por: Pham, Angeline, et al.
Publicado: (2021)

Antipsychotic-induced catatonia and neuroleptic malignant syndrome: the dark side of the moon
por: Hirjak, Dusan, et al.
Publicado: (2021)

Exercise and Worsening of Extrapyramidal Symptoms during Treatment with Long-Acting Injectable Antipsychotics
por: Kim, David D., et al.
Publicado: (2021)

Study on risk factors of extrapyramidal symptoms induced by antipsychotics and its correlation with symptoms of schizophrenia
por: Weng, Jiajun, et al.
Publicado: (2019)

Extrapyramidal side effects in first-episode schizophrenia treated with flupenthixol decanoate
por: Joubert, Francois-Pierre, et al.
Publicado: (2021)

Management of Psychosis in the Setting of Binge Eating, Mania, and Extrapyramidal Side Effects
por: Tamayo Acosta, Jean C, et al.
Publicado: (2022)

Extrapyramidal Side Effects with Chronic Atypical Antipsychotic Can Be Predicted by Labeling Pattern of FosB and phosphoThr(34)-DARPP-32 in Nucleus Accumbens
por: Prieto, Sonia G., et al.
Publicado: (2023)

Characteristics of Patients Experiencing Extrapyramidal Symptoms or Other Movement Disorders Related to Dopamine Receptor Blocking Agent Therapy
por: Musco, Shaina, et al.
Publicado: (2019)

Structure of the dopamine D(2) receptor in complex with the antipsychotic drug spiperone
por: Im, Dohyun, et al.
Publicado: (2020)

TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT(1A) receptor agonist SEP-363856
por: Saarinen, Marcus, et al.
Publicado: (2022)

Pharmacokinetic–Pharmacodynamic Modeling of Severity Levels of Extrapyramidal Side Effects With Markov Elements
por: Pilla Reddy, V, et al.
Publicado: (2012)

Extrapyramidal side-effects of low-dose aripiprazole in an 11-year-old child
por: Mohapatra, Satyakam
Publicado: (2016)

Extrapyramidal Side Effects with Low Dose Amisulpride: A Report of Two Cases
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2016)

Extrapyramidal side effect of donepezil hydrochloride in an elderly patient: A case report
por: Li, Hong-Chun, et al.
Publicado: (2020)

Erratum: Extrapyramidal side effects in first-episode schizophrenia treated with flupenthixol decanoate
por: Joubert, Francois-Pierre, et al.
Publicado: (2021)

Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses
por: Sahlholm, Kristoffer, et al.
Publicado: (2015)

Correction To: TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT(1A) receptor agonist SEP- 363856
por: Saarinen, Marcus, et al.
Publicado: (2022)

Differentiating Between Lithium Tremors and Extrapyramidal Tremors in a Patient on Long-Term Antipsychotics and Lithium Medication
por: Singh, Gurraj, et al.
Publicado: (2023)

PM432. Evaluation of the extrapyramidal side effects (EPS) liability of NMDA receptor glycine-binding site agonists
por: Ohno, Yukihiro, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hij21hf2srpff1t967gqonmibv